Viridian Therapeutics, Inc.\DE (VRDN) stock
Close on Nov 17, 2026Market cap $3.41BP/E –Yield –
Viridian Therapeutics, Inc.\DE grew revenue 23220.3% to $71.13M over the twelve months to Jun 30, 2026. Free cash flow was -$335.04M. At the latest close the market valued the company at $3.41B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $3.41B
- P/E ratio
- –
- Price to sales
- 47.88
- Price to book
- 5.14
- Dividend yield
- –
- Free cash flow yield
- -9.84%
Fundamentals
- Revenue
- $71.13M
- Net income
- -$386.97M
- Free cash flow
- -$335.04M
Trading
- Next earnings
- Feb 25, 2027 (estimated, before the open)
- Previous close
- $29.80
- Open
- $29.72
- Day's range
- $29.25 – $30.16
- Volume
- 1,812,269
- Average volume (20 days)
- 2,854,263
- Index membership
- Russell 2000 (since Jun 2022), Russell 3000 (since Aug 2022)
- 52-week range
- $13.18 – $34.29
- RSI (14 days)
- 70.1
- Volatility (1 year)
- 71.9%
- Relative volume
- 0.90×
On 1 of our idea list: Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2014, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.
| Period | VRDN | S&P 500 | Difference | VRDN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +58.0% | -4.0% | +62.0 pts | ||
| 3 months | +30.2% | -5.0% | +35.2 pts | ||
| Year to date | -3.4% | +8.2% | −11.7 pts | ||
| 1 year | +3.7% | +11.2% | −7.6 pts | ||
| 3 years | +89.3% | +68.5% | +20.8 pts | +23.7% | +19.0% |
| 5 years | +58.2% | +67.3% | −9.1 pts | +9.6% | +10.8% |
| 10 years | -71.9% | +291.6% | −363.5 pts | -11.9% | +14.6% |
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Viridian Therapeutics, Inc.\DE filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- Results
- Update
- Update
- Update
About Viridian Therapeutics, Inc.\DE
Pharmaceutical Preparations
This biopharmaceutical company focuses on discovering, developing, and commercializing targeted therapies for serious autoimmune and rare conditions. Its research and clinical pipeline centers on therapeutic candidates addressing validated biological pathways, notably thyroid eye disease and related autoimmune indications. The company's core development programs feature anti-insulin-like growth factor 1 receptor product candidates, including the intravenous monoclonal antibody veligrotug and subcutaneous elegrobart. In addition, its pipeline includes neonatal Fc receptor inhibitors, such as VRDN-006 and VRDN-008, alongside a thyroid-stimulating hormone receptor inhibitor program. Its end users are patients suffering from debilitating rare diseases, with commercial outreach targeting physicians and healthcare payors.
Company profile, executives and historyViridian Therapeutics, Inc.\DE stock: common questions
What is Viridian Therapeutics, Inc.\DE's stock price?
VRDN closed at $30.06 on Nov 17, 2026, up 0.87% on the day. Over the past 52 weeks it traded between $13.18 and $34.29.
What is Viridian Therapeutics, Inc.\DE's market cap?
Viridian Therapeutics, Inc.\DE was worth $3.41B at the close on Nov 17, 2026: the share price times the diluted shares outstanding.
How much revenue does Viridian Therapeutics, Inc.\DE make?
Viridian Therapeutics, Inc.\DE reported revenue of $71.13M for the twelve months to Jun 30, 2026, up 23220.3% from a year earlier.
Does Viridian Therapeutics, Inc.\DE pay a dividend?
No. Viridian Therapeutics, Inc.\DE has not paid a cash dividend over the last twelve months.
When does Viridian Therapeutics, Inc.\DE report earnings next?
Viridian Therapeutics, Inc.\DE is expected to report Q4 FY2026 results on Feb 25, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has VRDN stock performed over the past year?
Including dividends, VRDN returned +3.7% over the past year, against +11.2% for the S&P 500.
How many VRDN shares are sold short?
17M shares were sold short at the latest FINRA report, 19.23% of the float, or 9.1 days of average trading volume.
Who are Viridian Therapeutics, Inc.\DE's competitors?
Companies most similar to Viridian Therapeutics, Inc.\DE by business, industry and size include KROS, VTVT, ROIV, NAMS, ZNTL.
See a number that looks wrong?